Avalon GloboCare Completes Private Placement to Raise Capital

The latest update is out from Avalon GloboCare ( (ALBT) ).

On Feb. 26, 2026, Avalon GloboCare entered into securities purchase agreements with institutional investors for a private placement of common stock, pre-funded warrants, and Series A-1 and A-2 warrants priced at $0.51 per share or pre-funded warrant. The structure includes exercise caps to limit individual investor ownership and requires stockholder approval before the Series A warrants become exercisable, with expirations five years and 18 months after that approval, respectively.

The private placement closed on Feb. 27, 2026, delivering expected net proceeds of about $2.8 million from upfront gross proceeds of roughly $3.25 million, with up to approximately $6.5 million in additional potential proceeds if all warrants are exercised for cash. Avalon plans to use the funds to repay certain outstanding debt and for working capital and general corporate purposes, while recent net-share warrant exercises in February 2026 modestly increased the common share count without bringing in new cash, underscoring the company’s reliance on equity-linked financing to support operations.

H.C. Wainwright & Co. acted as exclusive placement agent, receiving cash fees, expense reimbursements, and placement agent warrants, and Roth Capital Partners served as financial advisor on the transaction. The securities were issued in a private placement to accredited investors under exemptions from SEC registration, with Avalon agreeing to register the resale of the new shares and warrant shares, a move aimed at providing liquidity to investors and potentially influencing future trading dynamics in the stock.

More about Avalon GloboCare

Avalon GloboCare Corp., listed on Nasdaq as ALBT, is a technology-focused company developing and acquiring artificial intelligence platforms, including automated video generation, enterprise documentation, and workflow automation through its Avalon Quantum AI subsidiary. The company is also expanding intellectual property in cellular therapy and generative AI publishing and software, while marketing the FDA-registered KetoAir breathalyzer and exploring additional diagnostic uses for the device.

Avalon targets the precision diagnostics and consumer health markets alongside enterprise AI software, positioning itself at the intersection of medical technology and next-generation AI tools. Its diversified portfolio reflects a strategy to blend regulated medical devices with scalable software and content solutions within high-growth, innovation-driven sectors.

Average Trading Volume: 6,572,607

Technical Sentiment Signal: Sell

Current Market Cap: $6.79M

Learn more about ALBT stock on TipRanks’ Stock Analysis page.